AKT-mediated phosphorylation of Sox9 induces Sox10 transcription in a murine model of HER2-positive breast cancer
Authors:
Open Access
- 13 May 2021
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research
- Vol. 23 (1) , 1-13
Abstract
Background: Approximately 5–10% of HER2-positive breast cancers can be defined by low expression of the Ste20-like kinase, SLK, and high expression of SOX10. Our lab has observed that genetic deletion of SLK results in the induction of Sox10 and significantly accelerates tumor initiation in a HER2-induced mammary tumor model. However, the mechanism responsible for the induction of SOX10 gene expression in this context remains unknown. Methods: Using tumor-derived cell lines from MMTV-Neu mice lacking SLK and biochemical approaches, we have characterized the signaling mechanisms and relevant DNA elements driving Sox10 expression. Results: Biochemical and genetic analyses of the SOX10 regulatory region in SLK-deficient mammary tumor cells show that Sox10 expression is dependent on a novel −7kb enhancer that harbors three SoxE binding sites. ChIP analyses demonstrate that Sox9 is bound to those elements in vivo. Our data show that AKT can directly phosphorylate Sox9 in vitro at serine 181 and that AKT inhibition blocks Sox9 phosphorylation and Sox10 expression in SLK(-/-) tumor cells. AKT-mediated Sox9 phosphorylation increases its transcriptional activity on the Sox10 −7kb enhancer without altering its DNA-binding activity. Interestingly, analysis of murine and human mammary tumors reveals a direct correlation between the levels of active phospho-Sox9 S181 and Sox10 expression. Conclusions: Our results have identified a novel Sox10 enhancer and validated Sox9 as a direct target for AKT. As Sox10 is a biomarker for triple-negative breast cancers (TNBC), these findings might have major implications in the targeting and treatment of those cancers.Keywords
Funding Information
- Canadian Institute of Health Reseach
- Canadian Cancer Society
- Canadian Breast Cancer Foundation
This publication has 52 references indexed in Scilit:
- A Sox10 enhancer element common to the otic placode and neural crest is activated by tissue-specific paralogsDevelopment, 2011
- HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapiesExpert Review of Anticancer Therapy, 2011
- Genomic code for Sox10 activation reveals a key regulatory enhancer for cranial neural crestProceedings of the National Academy of Sciences, 2010
- The Transcriptional Activity of Sox9 in Chondrocytes Is Regulated by RhoA Signaling and Actin PolymerizationMolecular and Cellular Biology, 2009
- An evolutionarily conserved intronic region controls the spatiotemporal expression of the transcription factor Sox10BMC Developmental Biology, 2008
- Identification of Neural Crest and Glial Enhancers at the Mouse Sox10 Locus through Transgenesis in ZebrafishPLOS Genetics, 2008
- FAK/src-Family Dependent Activation of the Ste20-Like Kinase SLK Is Required for Microtubule-Dependent Focal Adhesion Turnover and Cell MigrationPLOS ONE, 2008
- Multiple conserved regulatory elements with overlapping functions determine Sox10 expression in mouse embryogenesisNucleic Acids Research, 2007
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- Molecular mechanisms underlying ErbB2/HER2 action in breast cancerOncogene, 2000